11.10.2026
FDA Requires New Warning for NAION Risk Across All GLP-1 Receptor Agonists
The FDA is requiring updated safety labeling for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications following an evaluation identifying a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss. The agency is directing application holders to add information about NAION to the "Warnings and Precautions" section of product labeling.